Gynecologic Oncology | Interview with Michael Birrer, MD, PhD

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr Birrer on the following topics: Diagnosis and management of endometrial cancer with POLE mutation (00:00) Mechanism of action and tolerability of pembrolizumab/lenvatinib in patients with endometrial cancer (3:39) Clinical outcomes with and optimal integration of ICIs for ovarian cancer and cervical cancer (14:53) CME information and select publications